Quest Diagnostics 2011 Annual Report Download - page 26

Download and view the complete annual report

Please find page 26 of the 2011 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 123

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123

facilities, and its anatomic pathology testing services. Beginning in May 2011, she has had responsibility for
anatomic pathology and neurology testing services.
Kathy Ordon
˜ez (61) is Senior Vice President, Discovery and Development for Quest Diagnostics, and
President, Celera. Ms. Ordon
˜ez is responsible for managing the Company’s innovation pipeline and diagnostics
products businesses. In her role as President of Celera, she is responsible for leading Celera, including Berkeley
HeartLab, and driving its focus on personalizing disease management through diagnostic products and services.
Ms. Ordon
˜ez joined Quest Diagnostics with its acquisition of Celera in May 2011. She served as Chief Executive
Officer of Celera and was a founder of Celera Diagnostics. Prior to joining Celera’s parent company, Applera, in
December 2000, Ms. Ordon
˜ez held a number of senior positions over a 15-year period with Hoffmann La-Roche.
She oversaw the formation of Roche Molecular Systems, serving as President and Chief Executive Officer, and
led the application of polymerase chain reaction technology to the diagnostic, research and forensic fields.
Michael E. Prevoznik (50) is Senior Vice President and General Counsel. Mr. Prevoznik joined the Company
as Vice President and General Counsel in August 1999. Since April 2011, in addition to serving as General
Counsel, Mr. Prevoznik has had management responsibility for the Company’s international and clinical trials
activities. In 2003, he assumed responsibility for governmental affairs. Prior to joining the Company, Mr.
Prevoznik served in positions of increasing responsibility within the compliance organization at SmithKline
Beecham, most recently as Vice President, Compliance, with responsibility for coordinating all SmithKline
Beecham compliance activities worldwide.
20